Human Cytomegalovirus Envelope Glycoprotein B Industry Research Report 2025

Summary

According to APO Research, the global Human Cytomegalovirus Envelope Glycoprotein B market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Human Cytomegalovirus Envelope Glycoprotein B include Vical Incorporated, VBI Vaccine Inc, Vakzine Projekt Management GmbH, Trellis Bioscience, Inc. and Astellas Pharma Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Human Cytomegalovirus Envelope Glycoprotein B, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Cytomegalovirus Envelope Glycoprotein B.

The report will help the Human Cytomegalovirus Envelope Glycoprotein B manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.



The Human Cytomegalovirus Envelope Glycoprotein B market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Cytomegalovirus Envelope Glycoprotein B market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Human Cytomegalovirus Envelope Glycoprotein B Segment by Company

Vical Incorporated
VBI Vaccine Inc
Vakzine Projekt Management GmbH
Trellis Bioscience, Inc.
Astellas Pharma Inc.
Human Cytomegalovirus Envelope Glycoprotein B Segment by Type

CSJ-148
CyMVectin
PPCM
TRL-345
Cytomegalovirus Vaccine
Others
Human Cytomegalovirus Envelope Glycoprotein B Segment by Application

Infectious Disease
Women's Health
Oncology
Others
Human Cytomegalovirus Envelope Glycoprotein B Segment by Region


North America
United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Colombia
Middle East & Africa

Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Cytomegalovirus Envelope Glycoprotein B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Cytomegalovirus Envelope Glycoprotein B and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Cytomegalovirus Envelope Glycoprotein B.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Cytomegalovirus Envelope Glycoprotein B by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Cytomegalovirus Envelope Glycoprotein B in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size (2020-2031)
2.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales (2020-2031)
2.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Market Average Price (2020-2031)
2.3 Human Cytomegalovirus Envelope Glycoprotein B by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 CSJ-148
2.3.3 CyMVectin
2.3.4 PPCM
2.3.5 TRL-345
2.3.6 Cytomegalovirus Vaccine
2.3.7 Others
2.4 Human Cytomegalovirus Envelope Glycoprotein B by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Infectious Disease
2.4.3 Women's Health
2.4.4 Oncology
2.4.5 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units) of Manufacturers (2020-2025)
3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue of Manufacturers (2020-2025)
3.4 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Manufacturers (2020-2025)
3.5 Global Human Cytomegalovirus Envelope Glycoprotein B Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Product Type & Application
3.8 Global Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Established Date
3.9 Global Human Cytomegalovirus Envelope Glycoprotein B Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Vical Incorporated
4.1.1 Vical Incorporated Company Information
4.1.2 Vical Incorporated Business Overview
4.1.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
4.1.5 Vical Incorporated Recent Developments
4.2 VBI Vaccine Inc
4.2.1 VBI Vaccine Inc Company Information
4.2.2 VBI Vaccine Inc Business Overview
4.2.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
4.2.4 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
4.2.5 VBI Vaccine Inc Recent Developments
4.3 Vakzine Projekt Management GmbH
4.3.1 Vakzine Projekt Management GmbH Company Information
4.3.2 Vakzine Projekt Management GmbH Business Overview
4.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
4.3.5 Vakzine Projekt Management GmbH Recent Developments
4.4 Trellis Bioscience, Inc.
4.4.1 Trellis Bioscience, Inc. Company Information
4.4.2 Trellis Bioscience, Inc. Business Overview
4.4.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
4.4.5 Trellis Bioscience, Inc. Recent Developments
4.5 Astellas Pharma Inc.
4.5.1 Astellas Pharma Inc. Company Information
4.5.2 Astellas Pharma Inc. Business Overview
4.5.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
4.5.5 Astellas Pharma Inc. Recent Developments
5 Global Human Cytomegalovirus Envelope Glycoprotein B Market Scenario by Region
5.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2020-2031
5.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2020-2025
5.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2026-2031
5.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2020-2031
5.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2020-2025
5.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2026-2031
5.4 North America Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
5.4.1 North America Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
5.4.3 North America Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
5.5.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
5.5.3 Europe Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
5.6.1 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
5.6.3 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
5.7.1 South America Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
5.7.3 South America Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.7.7 Colombia
5.8 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
5.8.1 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
5.8.3 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2020-2031)
6.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2020-2031) & (W Units)
6.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Type (2020-2031)
6.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2020-2031)
6.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Type (2020-2031)
6.3 Global Human Cytomegalovirus Envelope Glycoprotein B Price by Type (2020-2031)
7 Segment by Application
7.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2020-2031)
7.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2020-2031) & (W Units)
7.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Application (2020-2031)
7.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2020-2031)
7.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Application (2020-2031)
7.3 Global Human Cytomegalovirus Envelope Glycoprotein B Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Human Cytomegalovirus Envelope Glycoprotein B Value Chain Analysis
8.1.1 Human Cytomegalovirus Envelope Glycoprotein B Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Human Cytomegalovirus Envelope Glycoprotein B Production Mode & Process
8.2 Human Cytomegalovirus Envelope Glycoprotein B Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Human Cytomegalovirus Envelope Glycoprotein B Distributors
8.2.3 Human Cytomegalovirus Envelope Glycoprotein B Customers
9 Global Human Cytomegalovirus Envelope Glycoprotein B Analyzing Market Dynamics
9.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Trends
9.2 Human Cytomegalovirus Envelope Glycoprotein B Industry Drivers
9.3 Human Cytomegalovirus Envelope Glycoprotein B Industry Opportunities and Challenges
9.4 Human Cytomegalovirus Envelope Glycoprotein B Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings